Edition:
United Kingdom

People: Zealand Pharma A/S (ZELA.CO)

ZELA.CO on Copenhagen Stock Exchange

97.00DKK
18 Jan 2019
Change (% chg)

kr.2.00 (+2.11%)
Prev Close
kr.95.00
Open
kr.98.00
Day's High
kr.100.80
Day's Low
kr.96.60
Volume
333,198
Avg. Vol
180,258
52-wk High
kr.127.00
52-wk Low
kr.78.60

Crane, Rosemary 

Ms. Rosemary A. Crane has been Independent Vice Chairman of the Board at Zealand Pharma A/S since April 21, 2015. Ms. Rosemary Crane has been CEO of Mela Sciences (2013-2014) and Epocrates (2008-2011), besides having held a number of senior positions in Johnson & Johnson and BMS. She is Member of the Board of Teva Pharmaceutical Industries Ltd. and Edge Therapeutics. Rose has a BA in Communication from the State University of New York, MBA from Kent State University.

Basic Compensation

Total Annual Compensation, DKK 400,000
Restricted Stock Award, DKK --
Long-Term Incentive Plans, DKK --
All Other, DKK --
Fiscal Year Total, DKK 400,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Alf Nicklasson

650,000

Britt Meelby Jensen

11,078,000

Rosemary Crane

400,000

Mats Blom

6,405,000

Ivan Moeller

--

Andrew Parker

--
As Of  31 Dec 2017